Group 1 - The core point of the article highlights that Fosun Pharma (01652) has deposited shares worth HKD 38.0688 million into Galaxy Securities Hong Kong, representing 5% of the total shareholding [1] - Fosun Pharma announced that its research and development product, "Metformin and Empagliflozin Tablets (I)", has received approval from the National Medical Products Administration of China for use in treating type 2 diabetes in adults [1] - The approved medication is intended to be used in conjunction with dietary control and exercise for patients already receiving treatment with Empagliflozin and Metformin hydrochloride to improve blood sugar control [1]

Group 1 - The core point of the article is that Fosen Pharmaceuticals has received approval from the National Medical Products Administration of China for its drug Metformin and Ertugliflozin Tablets, which is intended for the treatment of type 2 diabetes in adults [1] - On September 19, shareholders of Fosen Pharmaceuticals deposited shares worth HKD 38.0688 million into Galaxy Securities Hong Kong, representing 5% of the total shareholding [1]

Core Viewpoint - Fosun Pharma (01652) has announced the conditional sale of its subsidiary, Henan Fosun Smart Energy Technology Co., Ltd., to Henan Xisheng Industrial Development Co., Ltd. for a total consideration of RMB 73 million, as part of a strategic move to streamline operations and focus on its core pharmaceutical business [1][2]. Group 1 - The group primarily engages in the manufacturing and sales of pharmaceuticals [2]. - The target company specializes in the installation and operation of photovoltaic power generation systems, aimed at supporting the group's internal power needs and generating external sales revenue [2]. - The photovoltaic business is not a core focus of the group, leading to the decision to sell this non-core subsidiary [2]. Group 2 - The sale is a strategic action intended to consolidate resources, enhance operational efficiency, and reallocate management and financial focus back to the core pharmaceutical business [2]. - By restructuring its business portfolio and exiting peripheral industries, the group aims to strengthen its competitive position and enhance its ability to seize new growth opportunities in the pharmaceutical sector [2]. - The net proceeds from the sale will provide immediate cash inflow, intended for general working capital, including operational expenses and support for the ongoing development of the core pharmaceutical business [2]. - The board believes the terms of the sale are fair and reasonable, aligning with the overall interests of the company and its shareholders [2].

Core Viewpoint - Fosun Pharma (01652) has announced a conditional agreement to sell its subsidiary, Henan Fosun Smart Energy Technology Co., Ltd., to Henan Xisheng Industrial Development Co., Ltd. for a total consideration of RMB 73 million, as part of a strategic move to streamline operations and focus on its core pharmaceutical business [1] Group 1 - The group primarily engages in the manufacturing and sales of pharmaceuticals [1] - The target company specializes in the installation and operation of photovoltaic power generation systems, aimed at supporting the group's internal power needs and generating external revenue [1] - The photovoltaic business is not a core focus of the group, leading to the decision to divest this non-core subsidiary [1] Group 2 - The sale is a strategic action intended to consolidate resources, enhance operational efficiency, and reallocate management and financial focus back to the core pharmaceutical business [1] - By restructuring its business portfolio and exiting peripheral industries, the group aims to strengthen its competitive position and enhance its ability to seize new growth opportunities in the pharmaceutical sector [1] - The net proceeds from the sale will provide immediate cash inflow, intended for general working capital, including operational expenses and support for the ongoing development of its core pharmaceutical business [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 有關出售 河南福森智慧節能科技有限公司全部股權之 須予披露交易 出售事項 董事會謹此宣佈，於2025年9月19日（ 聯交所交易時段後 ），買方與賣方（ 本公司 之 間 接 全 資 附 屬 公 司 ）訂 立 該 協 議 ， 據 此 ， 賣 方 有 條 件 同 意 出 售 而 買 方 有 條 件 同意購買銷售股本，即目標公司之全部股權，總代價為人民幣73.0百萬元（ 相當 於約79.6百萬港元 ），惟須按及受限於該協議之條款。 上市規則之影響 由 於 出 售 事 項 之 最 高 適 用 百 分 比 率（ 定 義 見 上 市 規 則 ）超 過 5 % ， 但 所 有 適 用 百 分 ...

Group 1 - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - The early trading volume in Hong Kong stocks reached 160.2 billion HKD [1] Group 2 - New pharmaceutical stocks in the Hong Kong Stock Connect saw significant gains, with ZhiJie AnKang-B (02617) surging over 49%, reaching a market capitalization of over 240 billion HKD; BaiZe Medical (02609) rose over 76%; and TongYuanKang Pharmaceutical-B (02410) increased by over 36% [1] - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at 1.35 HKD, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company well-prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose over 6% as its "SoFast" service officially launched in Macau, with Daiwa optimistic about the company's revenue growth prospects [2] - Valiant Bio-B (09887) increased by over 13%, with its core product LBL-024 for melanoma completing its first patient dosing in trials [2] - Bilibili-W (09626) rose by 2.78%, accumulating a total increase of about 25% over the past six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - LionTeng Holdings (02562) surged over 7% as it plans to acquire leading companies in artificial intelligence and blockchain to expand its digital finance layout [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted placement to raise approximately 5.392 billion HKD for structural adjustments in polysilicon capacity [2] - China General Nuclear Power Corporation Mining (01164) increased by 6.7%, as the U.S. seeks to expand its strategic uranium reserves, with institutions expecting a recovery in uranium prices [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted placement to raise about 1.15 billion HKD [2]

Market Overview - The Hang Seng Index rose by 0.07%, gaining 19 points to close at 26,465 points, while the Hang Seng Tech Index increased by 0.39% [1] - Early trading volume in Hong Kong stocks reached HKD 160.2 billion [1] Notable Stock Movements - New pharmaceutical stocks in the Hong Kong Stock Connect surged, with Yaojie Ankang-B (02617) rising over 49%, reaching a market capitalization of over HKD 240 billion [1] - Baize Medical (02609) saw an increase of over 76% [1] - Tongyuan Kang Pharmaceutical-B (02410) rose by over 36% [1] Specific Company Highlights - Fosen Pharmaceutical (01652) experienced a dramatic rise of over 410%, closing at HKD 1.35, up 297%, following the approval of Metformin and Ertugliflozin tablets [2] - Shanghai Fudan (01385) increased by 5.87%, with the company prepared for supply chain disruptions, and Morgan Stanley noted limited impact on demand [2] - SF Express (09699) rose by over 6% as its "SoFast" service launched in Macau, with positive revenue growth prospects according to Daiwa [2] - Valiant Pharmaceuticals-B (09887) increased by over 13%, completing the first medication trial for its core product LBL-024 for melanoma [2] - Bilibili-W (09626) rose by 2.78%, accumulating a 25% increase over six days, with the new game "Three Kingdoms: Hundred Generals" set for testing in October [2] - Liontech Holdings (02562) surged over 7% as it plans to acquire a leading AI and blockchain company to expand its digital finance footprint [2] - GCL-Poly Energy (03800) rose by 3.97%, planning a discounted share placement to raise approximately HKD 5.392 billion for structural adjustments in polysilicon capacity [2] - CGN Mining (01164) increased by 6.7% amid expectations of rising uranium prices as the U.S. seeks to expand its strategic uranium reserves [2] - Yunfeng Financial (00376) fell over 16% after announcing a discounted share placement to raise about HKD 1.15 billion [2]

Core Viewpoint - The stock of Fosen Pharmaceutical in Hong Kong experienced significant volatility, with a peak increase of 400% during trading, ultimately settling at a 350% rise to HKD 1.53 [1] Group 1 - Fosen Pharmaceutical's stock surged dramatically, indicating strong market interest or potential news driving the price [1] - The stock's performance reflects a high level of trading activity, suggesting investor speculation or reaction to recent developments [1]

Core Viewpoint - Fosen Pharmaceutical (01652) experienced a significant stock price surge, rising over 410% at one point and currently up 350%, trading at HKD 1.53 with a transaction volume of HKD 13.89 million [1] Group 1: Company Developments - Fosen Pharmaceutical announced that its research and development product, "Metformin and Empagliflozin Tablets (I)", has received approval from the National Medical Products Administration of China [1] - The approved indication for the product is for the treatment of adult patients with type 2 diabetes who are currently receiving Empagliflozin and Metformin hydrochloride, aimed at improving blood glucose control in these patients [1] - The board believes that Metformin and Empagliflozin Tablets (I) is an important addition to the company's product pipeline in the diabetes treatment sector, providing more treatment options for diabetes patients [1]

Core Viewpoint - Fosen Pharmaceutical (01652) experienced a significant stock price surge, rising over 410% at one point and currently up 350% to HKD 1.53, with a trading volume of HKD 13.89 million [1] Group 1: Product Approval - Fosen Pharmaceutical announced that its research and development product, Metformin and Empagliflozin Tablets (I), has received approval from the National Medical Products Administration of China [1] - The product is indicated for the treatment of adult patients with type 2 diabetes who are currently receiving Empagliflozin and Metformin Hydrochloride, aimed at improving blood glucose control in these patients [1] - The board believes that Metformin and Empagliflozin Tablets (I) is an important addition to the company's product pipeline in the diabetes treatment sector [1] Group 2: Market Impact - The approval of this product is expected to provide more treatment options for a large number of diabetes patients [1]